Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $145.22 | 8 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $46.75 | 2 | $0 (2022) |
| Novo Nordisk Inc | $34.39 | 2 | $0 (2022) |
| SANOFI-AVENTIS U.S. LLC | $20.42 | 1 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $15.37 | 1 | $0 (2022) |
| Lilly USA, LLC | $15.20 | 1 | $0 (2024) |
| Amgen Inc. | $13.09 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $15.20 | 1 | Lilly USA, LLC ($15.20) |
| 2022 | $130.02 | 7 | Abbott Laboratories ($46.75) |
All Payment Transactions
8 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/16/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $15.20 | General |
| Category: Obesity | ||||||
| 12/13/2022 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $23.24 | General |
| Category: Diabetes Care | ||||||
| 11/29/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.63 | General |
| Category: Diabetes | ||||||
| 11/01/2022 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: Inflammation | ||||||
| 10/18/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Diabetes | ||||||
| 09/13/2022 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Diabetes Care | ||||||
| 08/30/2022 | Bayer HealthCare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.37 | General |
| Category: Cardio-renal | ||||||
| 08/23/2022 | SANOFI-AVENTIS U.S. LLC | SOLIQUA 100/33 (Biological) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 11 | 11 | $2,079 | $133.65 |
| 2022 | 18 | 604 | 638 | $89,232 | $35,628 |
| 2021 | 21 | 1,118 | 1,137 | $169,120 | $60,143 |
| 2020 | 57 | 8,088 | 10,309 | $633,169 | $156,191 |
All Medicare Procedures & Services
97 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 11 | 11 | $2,079 | $133.65 | 6.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 117 | 141 | $32,756 | $12,658 | 38.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 195 | 204 | $33,258 | $11,461 | 34.5% |
| 0241U | Respiratory infectious agent detection by rna for severe acute respiratory syndrome coronavirus 2 (covid 19), influenza a, influenza b, and respiratory syncytial virus, upper respiratory specimen, each reported as detected or not detected | Office | 2022 | 39 | 40 | $6,342 | $5,677 | 89.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 15 | $4,686 | $2,027 | 43.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 20 | 20 | $1,280 | $1,254 | 98.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 22 | 22 | $770.00 | $616.88 | 80.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 13 | 13 | $2,275 | $513.20 | 22.6% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $2,574 | $459.44 | 17.8% |
| 71046 | X-ray of chest, 2 views | Office | 2022 | 14 | 14 | $854.00 | $214.56 | 25.1% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 20 | 20 | $660.00 | $154.44 | 23.4% |
| 81001 | Manual urinalysis test with examination using microscope, automated | Office | 2022 | 43 | 43 | $602.00 | $135.68 | 22.5% |
| 83036 | Hemoglobin a1c level | Office | 2022 | 13 | 13 | $1,391 | $123.76 | 8.9% |
| 82565 | Blood creatinine level | Office | 2022 | 13 | 13 | $286.00 | $66.21 | 23.2% |
| 84295 | Blood sodium level | Office | 2022 | 13 | 13 | $273.00 | $62.18 | 22.8% |
| 84132 | Blood potassium level | Office | 2022 | 13 | 13 | $260.00 | $61.53 | 23.7% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 18 | 18 | $288.00 | $53.67 | 18.6% |
| 84520 | Urea nitrogen level to assess kidney function, quantitative | Office | 2022 | 13 | 13 | $221.00 | $51.07 | 23.1% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 12 | 12 | $456.00 | $38.52 | 8.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 296 | 305 | $46,360 | $20,130 | 43.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 126 | 126 | $28,980 | $11,659 | 40.2% |
| 0241U | Nfct ds vir resp rna 4 trgt | Office | 2021 | 63 | 65 | $27,820 | $9,271 | 33.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 31 | 31 | $10,323 | $4,186 | 40.5% |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | Office | 2021 | 50 | 50 | $15,000 | $3,750 | 25.0% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Office | 2021 | 43 | 43 | $11,524 | $3,322 | 28.8% |
About Dr. John Player, MD
Dr. John Player, MD is a Family Medicine healthcare provider based in Leland, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1629077615.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Player, MD has received a total of $145.22 in payments from pharmaceutical and medical device companies, with $15.20 received in 2024. These payments were reported across 8 transactions from 6 companies. The most common payment nature is "Food and Beverage" ($145.22).
As a Medicare-enrolled provider, Player has provided services to 9,821 Medicare beneficiaries, totaling 12,095 services with total Medicare billing of $252,096. Data is available for 4 years (2020–2023), covering 97 distinct procedure/service records.
Practice Information
- Specialty Family Medicine
- Location Leland, NC
- Active Since 07/20/2005
- Last Updated 03/18/2025
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1629077615
Products in Payments
- FREESTYLE LIBRE 2 (Device) $46.75
- Ozempic (Drug) $34.39
- SOLIQUA 100/33 (Biological) $20.42
- Kerendia (Drug) $15.37
- ZEPBOUND (Drug) $15.20
- Otezla (Drug) $13.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Leland
Kira Alatar, Md, MD
Family Medicine — Payments: $6,634
Robert Johnson, Md, MD
Family Medicine — Payments: $5,711
Dr. Anette Bodoky, M.d, M.D
Family Medicine — Payments: $3,461
Dr. Lekeshia Jarrett, Md, MD
Family Medicine — Payments: $2,607
Gloria Vreeland, M.d, M.D
Family Medicine — Payments: $1,629
Rajya Atluri, M.d, M.D
Family Medicine — Payments: $1,041